Safety, Pharmacokinetics, and Efficiency of JS005, a Novel Anti-interleukin-17A Monoclonal Antibody, in Healthy Chinese Adults and Patients with Moderate to Severe Psoriasis

JS005 is a novel anti-IL-17A monoclonal antibody. A Phase Ia study (Study 1) in healthy adults, followed by a Phase Ib/II study (Study 2) in patients with moderate to severe plaque psoriasis (PsO), were designed to evaluate the safety, efficacy, and pharmacokinetic characteristics of JS005. Study 1...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Lin Cai, Huichen Liu, Zhanglei Mu, Xiaohua Tao, Litao Zhang, Chunlei Zhang, Yumei Li, Guoqiang Zhang, Furen Zhang, Xiuqin Dong, Chengxin Li, Aijun Chen, Zhuning Wu, Yuxian Zhu, Mengqi Zhang, Jiangnian Liu, Aiming Li, Jianzhong Zhang
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Medical Journals Sweden 2025-03-01
Rangatū:	Acta Dermato-Venereologica
Ngā marau:	JS005 anti-IL-17A monoclonal antibody psoriasis
Urunga tuihono:	https://medicaljournalssweden.se/actadv/article/view/41105
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!